Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1697887

registered interest
date	21/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Attention Deficit Hyperactivity Disorder: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to give patients access to information on stock levels of ADHD medication at high street pharmacies; and whether her Department has made an assessment of the potential merits of giving patients access to the Medicines Supply Tool.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	19915
answer	answer is ministerial correction date of answer 26/03/2024 answer text <p>There were 10,558 community pharmacies in England on 29 February 2024, including 405 distance selling pharmacies. These contractors are independent private businesses contracted to provide services within the National Health Service. While the Department does not monitor their stock levels, it does have a role in managing supply at a national level to help ensure stocks are available from manufacturers to meet demand from patients across the country. We are often made aware of supply issues. Thankfully the vast majority can be managed with no impact to patients.</p><p>We work with the industry, the NHS, the Medicines and Healthcare products Regulatory Agency and others working across the supply chain to manage issues and we provide guidance for health care professionals about medicines that are experiencing supply issues on how to manage patients during a disruption where necessary.</p><p>The Medicine Supply Tool is designed to provide information and guidance for healthcare professionals, rather than members of the public. However, a public-facing page on attention deficit hyperactivity disorder medicine supply is available at the following link:</p><p><a href="https://www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd/" target="_blank">https://www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd/</a></p><p>Any patient who is worried about the supply of their medication should speak to their clinician, in the first instance.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 19916 question first answered 26/03/2024 15:22:10 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4510 label Biography information for Helen Hayes

1697888

registered interest
date	21/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Attention Deficit Hyperactivity Disorder: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the availability of information about stock levels of ADHD medication by high street pharmacies; and what steps is she taking to help ensure patients can identify pharmacies with stocks of their prescription.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	19916
answer	answer is ministerial correction date of answer 26/03/2024 answer text <p>There were 10,558 community pharmacies in England on 29 February 2024, including 405 distance selling pharmacies. These contractors are independent private businesses contracted to provide services within the National Health Service. While the Department does not monitor their stock levels, it does have a role in managing supply at a national level to help ensure stocks are available from manufacturers to meet demand from patients across the country. We are often made aware of supply issues. Thankfully the vast majority can be managed with no impact to patients.</p><p>We work with the industry, the NHS, the Medicines and Healthcare products Regulatory Agency and others working across the supply chain to manage issues and we provide guidance for health care professionals about medicines that are experiencing supply issues on how to manage patients during a disruption where necessary.</p><p>The Medicine Supply Tool is designed to provide information and guidance for healthcare professionals, rather than members of the public. However, a public-facing page on attention deficit hyperactivity disorder medicine supply is available at the following link:</p><p><a href="https://www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd/" target="_blank">https://www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd/</a></p><p>Any patient who is worried about the supply of their medication should speak to their clinician, in the first instance.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 19915 question first answered 26/03/2024 15:22:10 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4510 label Biography information for Helen Hayes

1692173

registered interest
date	27/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Estradiol
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the supply of Estradot patches for women with menopausal symptoms.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	15964
answer	answer is ministerial correction date of answer 06/03/2024 answer text <p>There are over 70 hormone replacement therapy (HRT) products licensed for supply in the United Kingdom. There have been issues with the supply of a limited number of HRT products, primarily due to very sharp increases in demand, but the supply position has improved considerably over the last year, following intensive work with industry. We have held roundtables, and continue to do so, with suppliers, wholesalers, and community pharmacists to discuss the challenges they are facing, and what needs to be done to address them.</p><p>Intermittent supply issues were affecting estradot patches, which resulted in the use of a Serious Shortage Protocol, to allow pharmacists to supply an alternative brand of estradiol patches where estradot patches were not available. However, the issues have now been resolved and supplies should be available. We are continuing to engage closely with the supplier to monitor the supply position and drive action.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 15965 question first answered 06/03/2024 17:16:54 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4510 label Biography information for Helen Hayes

1692174

registered interest
date	27/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Estradiol
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help resolve supply chain issues for Estradot patches; and whether she has made an assessment of the potential impact of the UK’s withdrawal from the EU on such supplies.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	15965
answer	answer is ministerial correction date of answer 06/03/2024 answer text <p>There are over 70 hormone replacement therapy (HRT) products licensed for supply in the United Kingdom. There have been issues with the supply of a limited number of HRT products, primarily due to very sharp increases in demand, but the supply position has improved considerably over the last year, following intensive work with industry. We have held roundtables, and continue to do so, with suppliers, wholesalers, and community pharmacists to discuss the challenges they are facing, and what needs to be done to address them.</p><p>Intermittent supply issues were affecting estradot patches, which resulted in the use of a Serious Shortage Protocol, to allow pharmacists to supply an alternative brand of estradiol patches where estradot patches were not available. However, the issues have now been resolved and supplies should be available. We are continuing to engage closely with the supplier to monitor the supply position and drive action.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 15964 question first answered 06/03/2024 17:16:54 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4510 label Biography information for Helen Hayes

1692175

registered interest
date	27/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Menopause: Mental Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate she has made of the average waiting time for cognitive behavioural therapy for women with menopausal symptoms in London.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	15966
answer	answer is ministerial correction date of answer 05/03/2024 answer text <p>Improving care and support for menopause is a priority in the Women’s Health Strategy. It is important that all women experiencing the menopause have access to information and options to enable them to choose the best care to suit them. The National Institute for Health and Care Excellence’s guidelines currently recommend that that cognitive behavioural therapy (CBT) can be recommended for low mood or anxiety that arises as a result of the menopause.</p><p>CBT is offered as part of the NHS Talking Therapies services. The latest data for NHS Talking Therapies in the London region shows that 35,410 females, including trans women, accessed National Health Service funded treatment during the period from October to December 2023. Of these, 91% completing treatment waited less than six weeks for their first appointment, against a target of 75%, and 98% completing treatment waited less than 18 weeks, against a target of 95%. Data is not collected separately for CBT, which is one type of talking therapy. Data is also not collected separately for females with menopausal symptoms. This data is available at the following link:</p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/nhs-talking-therapies-monthly-statistics-including-employment-advisors/performance-december-2023-and-quarter-3-2023-24-data" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/nhs-talking-therapies-monthly-statistics-including-employment-advisors/performance-december-2023-and-quarter-3-2023-24-data</a></p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 05/03/2024 11:57:12 answering member 4492 label Biography information for Maria Caulfield
tabling member	4510 label Biography information for Helen Hayes

1689963

registered interest
date	19/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Spinal Injuries: Continuing Care
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of applications for NHS continuing healthcare received in each of the last two years came from patients who became tetraplegic as a result of a spinal injury; how many and what proportion of those applications were granted; and if she will provide a breakdown of those figures by integrated care board area.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	14649
answer	answer is ministerial correction date of answer 22/02/2024 answer text <p>Data is not collected on the specific medical conditions of people who apply for NHS Continuing Healthcare (CHC). Eligibility for CHC is not determined by age, diagnosis or condition, or financial means. It is assessed on a case-by-case basis taking into account the totality of an individual’s needs, including ways in which these needs interact with one another.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 14650 question first answered 22/02/2024 11:32:24 answering member 4527 label Biography information for Helen Whately
tabling member	4510 label Biography information for Helen Hayes

1690117

registered interest
date	19/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Spinal Injuries: Continuing Care
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of applications for NHS continuing healthcare received in each of the last two years came from patients with autonomic dysreflexia; how many and what proportion of those applications were granted; and if she will provide a breakdown of those figures by integrated care board area.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	14650
answer	answer is ministerial correction date of answer 22/02/2024 answer text <p>Data is not collected on the specific medical conditions of people who apply for NHS Continuing Healthcare (CHC). Eligibility for CHC is not determined by age, diagnosis or condition, or financial means. It is assessed on a case-by-case basis taking into account the totality of an individual’s needs, including ways in which these needs interact with one another.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 14649 question first answered 22/02/2024 11:32:24 answering member 4527 label Biography information for Helen Whately
tabling member	4510 label Biography information for Helen Hayes

1684809

registered interest
date	24/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Infant Foods: Inflation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential impact of inflation on the cost of formula milk.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	11376
answer	answer is ministerial correction date of answer 29/01/2024 answer text <p>The Competition and Market Authority (CMA) published a report in November 2023 named ‘Price inflation and competition in food and grocery manufacturing and supply’, which included an assessment on infant formula. It found that between March 2021 and April 2023, the price of infant formula had grown beyond the increased input costs to manufacturers. The report is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/price-inflation-and-competition-in-food-and-grocery-manufacturing-and-supply" target="_blank">https://www.gov.uk/government/publications/price-inflation-and-competition-in-food-and-grocery-manufacturing-and-supply</a></p><p>The CMA has committed to publishing a further report examining infant formula in more detail later this year, and Departmental officials continue to engage with the CMA.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom grouped question UIN 11377 question first answered 29/01/2024 15:39:54 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4510 label Biography information for Helen Hayes

1684810

registered interest
date	24/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Infant Foods: Competition and Markets Authority
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions her Department has had with the Competition and Markets Authority on the baby formula market.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	11377
answer	answer is ministerial correction date of answer 29/01/2024 answer text <p>The Competition and Market Authority (CMA) published a report in November 2023 named ‘Price inflation and competition in food and grocery manufacturing and supply’, which included an assessment on infant formula. It found that between March 2021 and April 2023, the price of infant formula had grown beyond the increased input costs to manufacturers. The report is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/price-inflation-and-competition-in-food-and-grocery-manufacturing-and-supply" target="_blank">https://www.gov.uk/government/publications/price-inflation-and-competition-in-food-and-grocery-manufacturing-and-supply</a></p><p>The CMA has committed to publishing a further report examining infant formula in more detail later this year, and Departmental officials continue to engage with the CMA.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom grouped question UIN 11376 question first answered 29/01/2024 15:39:54 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4510 label Biography information for Helen Hayes

1680889

registered interest
date	09/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	IVF
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what data her Department holds on the number and proportion of integrated care boards offering three full cycles of IVF in line with NICE guidelines as of 9 January 2023.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	8786
answer	answer is ministerial correction date of answer 18/01/2024 answer text <p>As part of the first-year commitments in the Women’s Health Strategy, the Government published our in-vitro fertilisation (IVF) transparency tool on GOV.UK in July 2023. This tool compiles published integrated care board (ICB) policies on their local fertility treatment offer to keep track nationally of implementation progress.</p><p>From the data compiled from published ICB commissioning policy statements, currently three out of 42 ICBs provide three full IVF cycles in line with National Institute for Health and Care Excellence fertility guidelines.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 18/01/2024 15:39:25 answering member 4492 label Biography information for Maria Caulfield
tabling member	4510 label Biography information for Helen Hayes